Tagrisso is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with non-small-cell lung cancer whose tumors are positive for epidermal growth factor receptor (EGFR) exon 19 deletions, exon 21 L858R mutations, or EGFR T790M mutations detected by an FDA-approved test. Tagrisso is also referred to by its drug name, osimertinib.
Tagrisso is a member of a class of drugs called tyrosine kinase inhibitors. Tagrisso is believed to work by binding to specific mutant kinases on cancer cells. This binding prevents cancer cells from receiving growth factors they need to reproduce, thus inhibiting cancer cell replication and slowing the growth of tumors.
How do I take it?
Prescribing information states that Tagrisso is taken orally as a tablet once daily.
Tagrisso should be taken exactly as prescribed by a physician.
The FDA-approved label for Tagrisso lists common side effects including low red and white blood cell counts, diarrhea, rash, musculoskeletal pain, dry skin, oral inflammation and ulcers, fatigue, and cough.
Rare but serious side effects listed for Tagrisso include abnormal heart rhythm, heart muscle disease, keratitis (inflammation of the cornea of the eye), fetal harm, a severe and potentially fatal skin reaction known as Stevens-Johnson syndrome, and interstitial lung disease (scarring of the lungs).
For more details about this treatment, visit:
Tagrisso — AstraZeneca
Osimertinib (Oral Route) — Mayo Clinic